MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10507256261416838

Медицинская библиотека · Thyroid : official journal of the American Thyroid Association · 2026

Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial.

Gui Lin, Zhu Haohua, Tang Le, Zhu Yiming, Zhang Ye, Lu Haizhen, Li Weihua, Yao Jiarui, Ni Song, Liu Shaoyan, Shi Yuankai

СтатьяКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy. Dabrafenib plus trametinib has shown efficacy in BRAFV600E-mutant ATC, but effective therapies remain limited for patients without this mutation. This study aimed to evaluate the efficacy and safety of anlotinib plus sintilimab in BRAFV600E-negative ATC.

METHODS

In this phase 2 trial, patients with BRAFV600E-negative unresectable or metastatic ATC received anlotinib (12 mg orally once daily on days 1-14 of a 21-day cycle) plus sintilimab (200 mg intravenously on day 1). The primary endpoint was investigator-assessed objective response rate (ORR). This study is registered at www.chictr.org.cn, ChiCTR2200067045.

RESULTS

From December 27, 2022, to June 11, 2025, 21 patients were enrolled. One (4.8%) patient achieved complete response, and nine (42.9%) patients achieved partial response. The ORR and disease control rate were 47.6% (10/21) and 85.7% (18/21), respectively. After median follow-up of 9.97 months (confidence interval [CI] 6.10 to NA), 61.9% (13/21) of patients had discontinued treatment, mainly due to disease progression (7/21, 33.3%), adverse events (AEs) (2/21, 9.5%), and other reasons (4/21, 19.0%). Median progression-free survival (PFS) was 9.63 months (CI 4.03 to NA), with eight (38.1%) patients were still on treatment. Subgroup analysis showed longer PFS in patients with neutrophil-lymphocyte ratio <3.06 (18.43 vs. 3.67 months; p = 0.010) and <5 (14.23 vs. 2.67 months; p = 0.002). Median overall survival was not reached (CI 13.90 to NA), 15 (71.4%) patients remained alive. AEs occurred in 66.7% (14/21) of patients, including grade 3 AEs in 19.0% (4/21). The most common were aspartate aminotransferase (AST) increased (6/21, 28.6%) and alanine aminotransferase (ALT) increased (5/21, 23.8%). Grade 3 immune-related AEs occurred in three patients, including AST/ALT increased, diarrhea, hypertension, and hypertriglyceridemia.

CONCLUSIONS

Anlotinib plus sintilimab showed favorable efficacy and manageable safety in BRAFV600E-negative unresectable or metastatic ATC, supporting further investigation.

Для цитирования: Gui Lin, Zhu Haohua, Tang Le, Zhu Yiming, Zhang Ye, Lu Haizhen, Li Weihua, Yao Jiarui, Ni Song, Liu Shaoyan, Shi Yuankai. Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial.. Thyroid : official journal of the American Thyroid Association. 2026. DOI: 10.1177/10507256261416838.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.